Objectives
Determine whether patients who have acquired the human immunodeficiency virus through injecting drug use receive less antiviral medication (zidovudine) than comparable patients of other risk groups considering access to, acceptance of, and compliance with treatment.
Design
Historical cohort study.
Setting
Human immunodeficiency virus outpatient clinic.
Patients
Human immunodeficiency virus—infected subjects eligible for zidovudine treatment between January 1, 1989, and January 1, 1992, comparing injecting drug users (IDUs) with non-IDUs ("others").
Main Outcome Measures
Proposal, acceptance, start of, and compliance with zidovudine treatment.
Results
One hundred fifty-one IDUs and 162 other human immunodeficiency virus—positive subjects became eligible for zidovudine treatment between January 1, 1989, and January 1, 1992. Both groups were proposed zidovudine as often, but zidovudine treatment was refused by 14.9% of IDUs compared with 7.1% of others (P=.029). The IDUs needed considerably more time than other subjects to accept zidovudine therapy (median delay between indication and start of zidovudine treatment, 61 days vs 30 days, P=.0001). After accepting, IDUs were as compliant with treatment as others: 81.3% vs 83.2% were good compliers, and rises of mean corpuscular volume of erythrocytes after 3 and 6 months of treatment were similar in both groups. Former drug users and IDUs receiving methadone were started on zidovudine treatment more often and complied better with treatment than active drug users. Absence of housing and presence of psychiatric diagnosis (both more prevalent in IDUs) were associated with less zidovudine treatment and worse compliance.
Conclusion
Injecting drug users tend to delay the start of zidovudine treatment. However, once they have started, their compliance is no worse than the compliance of patients from other risk groups. These results have important implications for clinical trials, medical care, and public health.
(Arch Intern Med. 1994;154:1121-1127)
Adherence to Antiretroviral Therapy: The Emerging Role of HIV Pharmacotherapy Specialists
Hardy
Journal of Pharmacy Practice 2005;18:247-257.
ABSTRACT
Psychiatric Barriers to Readiness for Treatment for Hepatitis C Virus (HCV) Infection among Injection Drug Users: Clinical Experience of an Addiction Psychiatrist in the HIV-HCV Coinfection Clinic of a Public Health Hospital
Scheft and Fontenette
Clinical Infectious Diseases 2005;40:S292-S296.
ABSTRACT
| FULL TEXT
Psychiatric Morbidity and Adherence to Antiretroviral Medication in Patients With HIV/AIDS
Sternhell and Corr
Aust N Z J Psychiatry 2002;36:528-533.
ABSTRACT
| FULL TEXT
Perceptions of disease and therapy are factors influencing adherence to antiretroviral therapy
Martini et al.
Sex. Transm. Infect. 2000;76:496-497.
FULL TEXT
Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996
Schwarcz et al.
Am J Epidemiol 2000;152:178-185.
ABSTRACT
| FULL TEXT
Adherence and Antiretroviral Therapy in Injection Drug Users
Sherer
JAMA 1998;280:567-568.
FULL TEXT
Public Health Implications of Antiretroviral Therapy and HIV Drug Resistance
Wainberg and Friedland
JAMA 1998;279:1977-1983.
ABSTRACT
| FULL TEXT
Determinants of Nontraditional Therapy Use in Patients With HIV Infection: A Prospective Study
Singh et al.
Arch Intern Med 1996;156:197-201.
ABSTRACT
Provider Assessments of Compliance With Zidovudine-Reply
Hirschel et al.
Arch Intern Med 1995;155:336-336.
ABSTRACT
Provider Assessments of Compliance With Zidovudine
Steiner
Arch Intern Med 1995;155:335-336.
ABSTRACT
